CN115671242A - Traditional Chinese medicine compound preparation for treating gastric precancerous lesions - Google Patents
Traditional Chinese medicine compound preparation for treating gastric precancerous lesions Download PDFInfo
- Publication number
- CN115671242A CN115671242A CN202211496019.0A CN202211496019A CN115671242A CN 115671242 A CN115671242 A CN 115671242A CN 202211496019 A CN202211496019 A CN 202211496019A CN 115671242 A CN115671242 A CN 115671242A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- preparation
- gastric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Abstract
The invention relates to the technical field of traditional Chinese medicine compositions, in particular to a traditional Chinese medicine compound preparation for treating gastric precancerous lesion, which is named as Erbai pseudo-ginseng disease-eliminating decoction and is a traditional Chinese medicine composition prepared from the following raw material medicines: white atractylodes rhizome, notoginseng powder, oldenlandia diffusa, poria cocos, coptis root, curcuma zedoary and dandelion. The traditional Chinese medicine compound preparation has the effects of tonifying qi and activating blood, clearing heat and eliminating dampness, and detoxifying and eliminating illness, can be applied to treatment of qi deficiency and blood stasis and damp-heat toxin accumulation type gastric precancerous lesion, and especially has obvious curative effects on slowing down intestinal epithelization and atypical hyperplasia in the middle and late stages of the precancerous lesion. The traditional Chinese medicine compound preparation has simple medicine composition, no rare medicinal materials, low preparation cost and convenient large-scale popularization.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicine compositions, in particular to a traditional Chinese medicine compound preparation for treating gastric precancerous lesions.
Background
Precancerous lesions (plcc) are a pathological concept, referring to a group of pathological histological changes of gastric mucosa that are easily cancerated, including Intestinal Metaplasia (IM) and Dysplasia (dyspasia, dys), mainly accompanied by ChroniC AtroPhiC Gastritis (ChroniC atropic gastric disease, CAG), which is an important stage in the transformation process from normal gastric mucosa to gastric cancer. The currently consistently recognized transformation patterns are: chronic atrophic gastritis → gastric mucosa enterocele → large intestine enterocele → atypical hyperplasia → gastric cancer.
The western medicine has no effective medicine for treating gastric precancerous lesion at present, the traditional Chinese medicine combines disease differentiation and dialectical analysis, gives full play to the characteristics of the traditional Chinese medicine, and widely discusses the treatment prescription of the gastric precancerous lesion to form a plurality of prescriptions.
1. Addition and subtraction study of famous prescription
Flood, wuhan and so on [1] The observation of the clinical effect of the pinellia ternate heart-fire clearing decoction on the treatment of the syndrome of cold-heat complicated with lumps in the stomach precancerous lesions shows that the modified pinellia ternate heart-fire clearing decoction can improve the gastric mucosa by regulating the functions of the spleen and the stomach, increasing the blood supply of the gastric mucosa and promoting the gastric microcirculation for the treatment of the syndrome of dampness-heat in the spleen and the stomach precancerous lesions of the stomach precancerous lesionsPathological changes and clinical symptoms, improving the curative effect of the traditional Chinese medicine syndrome and reducing the cancer rate. Lijunling [2] The influence of the four-monarch decoction on the expression of MCT, MCT4 and CD147 of the gastric mucosa of a rat model for treating gastric precancerous lesions is observed, and the result shows that the four-monarch decoction can obviously improve the abnormal histopathology of the gastric mucosa epithelium of the rat model for GPL and can reduce the over-expression of the MCT4 and the CD 147.
2. Study of formulation by oneself
Xu ya ban et al [3] The recipe for eliminating turbid pathogen and detoxifying is prepared by self, and the curative effect of the recipe for benefiting the stomach, eliminating turbid pathogen and detoxifying in combination with the vitamin tablets on chronic atrophic gastritis and gastric precancerous lesion and the influence on Ki-67 protein expression are discussed. Shows that the stomach-benefiting, turbid-removing and detoxifying combination with the vitamin tablet can effectively improve clinical symptoms and pathological histological pathological change states of patients with chronic atrophic gastritis and precancerous gastric lesion, and reduce the positive rate of Ki-67 protein expression of gastric mucosa. Qi directional war [4] The five-Dan Weifu granules are prepared by self, the mechanism that the five-Dan Weifu granules intervene in pre-gastric lesion (PLGC) rats is discussed based on a PI3K/Akt signal channel, and the five-Dan Weifu granules are found to reduce the expression of eNOS, NF-kB and COX-2 by influencing the PI3K/Akt signal channel of the PLGC rats, so that the development of the PLGC to gastric cancer is delayed.
In conclusion, prevention or treatment of precancerous lesions of the stomach cancer and prevention of precancerous lesion transformation into the stomach cancer are important ways for preventing and treating the stomach cancer, but the treatment formula is complicated and disorderly, the composition and the dosage are unimportant, the curative effect level is fuzzy and subjective, the patient is confused in taking medicine for medical treatment, and therefore a prescription which is objective and controllable in curative effect and clear and definite in medicine composition and treatment mechanism is urgently needed to be summarized, summarized and standardized. Reference:
[1] the observation of the curative effect of the modified pinellia tuber heart-fire-purging decoction for treating the spleen and stomach damp-heat syndrome with gastric precancerous lesions based on the theory of damp-heat collateral-resistance [ J ]. Hebei Chinese medicine, 2022,44 (03): 388-392+484.
[2] Supplement and improve the acid microenvironment to reverse precancerous lesion of gastric cancer based on MCT4/CD147 discussion of four Jun decoction [ J ] Chinese journal of Experimental and prescriptions, 2021,27 (06): 30-36.
[3] Xu ya pei, li Bolin, xuwei Chao, yang Xinfeng, long run, wu Chun Xiao, du Peng Li, yu Ru, wang Xiao Tian, yan Jing, yiwei Hua Zheng Zhuo Ji Fang combined with Wei Su pian for treating chronic atrophic gastritis gastric precancerous lesion and the influence on Ki-67 protein expression [ J ] modern J.Med.Med.Med.Med.Med.J., 2021,30 (36): 4018-4022.
[4] The experimental study on the influence of Wudan Weifu granules on the PI3K/Akt signal pathway of pre-gastric lesion rats [ J/OL ]. Liaoning journal of traditional Chinese medicine: 1-9.
Disclosure of Invention
Aiming at the dilemma of the treatment of the gastric precancerous lesion at present, the invention systematically excavates by means of a big data analysis method on the basis of widely collecting the big data of the treatment formula of the gastric precancerous lesion in the past, verifies the clinical and experimental results, and determines the formula as 'Erbai pseudo-ginseng illness-eliminating soup' according to the naming mode of 'main medicine + main efficacy'. The invention aims to provide a traditional Chinese medicine compound preparation for treating gastric precancerous lesions, which is applied to treatment of the gastric precancerous lesions caused by qi deficiency, blood stasis and damp-heat toxin accumulation.
In order to achieve the purpose, the invention adopts the following technical scheme.
A traditional Chinese medicine compound preparation for treating gastric precancerous lesion, named as Erbai pseudo-ginseng disease-eliminating decoction, is a traditional Chinese medicine composition prepared from the following raw material medicines in parts by weight: 7 to 12 portions of largehead atractylodes rhizome, 1 to 5 portions of pseudo-ginseng powder, 28 to 32 portions of spreading hedyotis herb, 10 to 14 portions of Indian buead, 4 to 8 portions of golden thread, 8 to 12 portions of zedoary and 13 to 17 portions of dandelion.
Preferably, the traditional Chinese medicine compound preparation for treating gastric precancerous lesion is prepared from the following raw material medicines in parts by weight: 8 to 10 parts of largehead atractylodes rhizome, 2 to 4 parts of pseudo-ginseng powder, 29 to 31 parts of spreading hedyotis herb, 11 to 13 parts of tuckahoe, 5 to 7 parts of coptis root, 9 to 11 parts of zedoary and 14 to 16 parts of dandelion.
Preferably, the traditional Chinese medicine compound preparation for treating gastric precancerous lesion is prepared from the following raw material medicines in parts by weight: 9 parts of bighead atractylodes rhizome, 3 parts of pseudo-ginseng powder, 30 parts of spreading hedyotis herb, 12 parts of poria cocos, 6 parts of coptis chinensis, 10 parts of curcuma zedoary and 15 parts of dandelion.
A preparation method of a traditional Chinese medicine compound preparation for treating gastric precancerous lesions comprises the following steps:
weighing each group of medicines, respectively putting the medicines except the pseudo-ginseng powder into a medicine pot, weighing 2 times of water in the volume of the medicines in the medicine pot, pouring the water into the medicine pot, soaking the medicines for 0.5h, then starting decoction, firstly boiling the medicines with strong fire to boil, then boiling the medicines with slow fire for 0.5h, filtering the decocted first-time liquid medicine with eight layers of clean medical gauze, pouring the filtered liquid medicine into a clean container, keeping dregs of a decoction, then adding the water with the same volume as the first-time liquid medicine for second-time decoction, repeating the steps, combining the filtrates, pouring the pseudo-ginseng powder into the liquid medicine, uniformly stirring the mixed solution, and then taking the mixed solution at a warm temperature.
Wherein the strong fire is 150-220 ℃, and the slow fire is 80-120 ℃.
The invention also provides granules for treating chronic gastritis and precancerous lesions of gastric cancer, wherein the granules comprise the traditional Chinese medicine composition and preparation auxiliary materials; the adjuvants include one or more of filler (such as starch and sugar powder), binder (such as dextrin and gelatin slurry), wetting agent (such as distilled water), disintegrant (such as dried starch), lubricant (such as hydrogenated vegetable oil), and film coating material (hydroxypropyl methylcellulose).
The invention also provides an oral liquid for treating chronic gastritis and precancerous lesions of gastric cancer, which comprises the traditional Chinese medicine composition and preparation auxiliary materials; the adjuvants include one or more of solvent (such as water and glycerol), aromatic (such as peppermint water and cassia oil), correctant (such as sucrose and stevioside), clarifier (such as ZTC1+ 1) and antiseptic (such as sorbic acid).
The invention also provides a tablet for treating chronic gastritis and gastric precancerous lesions, which comprises the traditional Chinese medicine composition and preparation auxiliary materials; the adjuvants include one or more of diluent (such as modified starch and microcrystalline cellulose), binder (such as starch slurry and gelatin slurry), lubricant (such as magnesium stearate), and disintegrant (such as dried starch).
The invention also provides a capsule for treating chronic gastritis and precancerous lesions of gastric cancer, which comprises the traditional Chinese medicine composition and preparation auxiliary materials; the preparation auxiliary material is a hard capsule shell or a soft capsule shell.
The invention also provides powder for treating chronic gastritis and precancerous lesions of gastric cancer, which comprises the traditional Chinese medicine composition.
The pharmaceutical composition provided by the invention can be prepared into granules, oral liquid, tablets, capsules and powder, and is more convenient to take, carry and store. The preparation auxiliary materials are all conventional auxiliary materials for the preparation.
The invention also provides application of the traditional Chinese medicine composition in preparing medicines for treating chronic gastritis, chronic atrophic gastritis, precancerous lesion of gastric cancer, chronic atrophic gastritis with intestinal metaplasia and abnormal hyperplasia.
The formula structure and the pharmacological effects of the components of the traditional Chinese medicine compound preparation are as follows:
the monarch drug, rhizoma Atractylodis Macrocephalae, has the effects of invigorating qi, strengthening the spleen, eliminating dampness and inducing diuresis.
The ministerial drug of pseudo-ginseng, which has the effects of removing blood stasis, stopping bleeding, relieving swelling and pain; oldenlandia diffusa has the functions of clearing heat and removing toxicity, and promoting diuresis and removing dampness.
The tuckahoe is used for excreting dampness and strengthening spleen and is matched with the white atractylodes rhizome to form a typical medicine pair for tonifying qi and strengthening spleen, which is mainly used for tonifying and can tonify without stagnation;
the assisted coptis chinensis and the dandelion help the oldenlandia to clear heat, dry dampness and detoxify;
the zedoary helps the pseudo-ginseng break blood, promote qi circulation and eliminate mass, and the pseudo-ginseng is combined to stop bleeding without retaining stasis and activate blood without damaging healthy qi.
The medicines are used together to play the effects of invigorating qi and activating blood circulation, clearing heat and eliminating dampness, and detoxifying and eliminating illness.
The invention has the beneficial effects that:
the traditional Chinese medicine compound preparation for treating precancerous lesions of the stomach cancer has the effects of tonifying qi and activating blood, clearing heat and eliminating dampness, detoxifying and eliminating mass, can be applied to treatment of precancerous lesions of the stomach cancer with qi deficiency and blood stasis and accumulation of damp-heat toxin, and has obvious curative effects on the moderate and severe symptoms of intestinal metaplasia and atypical hyperplasia in the middle and later stages of the precancerous lesions of the stomach cancer. The traditional Chinese medicine compound preparation has simple medicine composition, no rare medicinal materials, low preparation cost and convenient large-scale popularization.
Drawings
Fig. 1 is a comparison chart of pathological observation (HE staining) images of prevention and treatment of gastric precancerous lesion of the traditional Chinese medicine compound preparation (Erbai pseudo-ginseng and abdominal mass-eliminating decoction) for treating gastric precancerous lesion.
Detailed Description
In order that the above objects, features and advantages of the present invention can be more clearly understood, a more particular description of the invention, taken in conjunction with the accompanying drawings and detailed description, is set forth below. In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present invention, however, the present invention may be practiced otherwise than as specifically described herein and, therefore, the present invention is not limited to the specific embodiments disclosed below.
Example 1
A traditional Chinese medicine compound preparation for treating gastric precancerous lesion, named as Erbai pseudo-ginseng disease-eliminating decoction, is a traditional Chinese medicine composition prepared from the following raw material medicines in parts by weight: 9g of bighead atractylodes rhizome, 3g of pseudo-ginseng powder, 30g of spreading hedyotis herb, 12g of poria cocos, 6g of coptis chinensis, 10g of curcuma zedoary and 15g of dandelion.
Example 2
A traditional Chinese medicine compound preparation for treating gastric precancerous lesion, named as Erbai pseudo-ginseng disease-eliminating decoction, is a traditional Chinese medicine composition prepared from the following raw material medicines in parts by weight: 12g of bighead atractylodes rhizome, 4g of pseudo-ginseng powder, 40g of spreading hedyotis herb, 16g of poria cocos, 8g of coptis chinensis, 12g of curcuma zedoary and 20g of dandelion.
Example 3
A traditional Chinese medicine compound preparation for treating gastric precancerous lesion, named as Erbai pseudo-ginseng disease-eliminating decoction, is a traditional Chinese medicine composition prepared from the following raw material medicines in parts by weight: 6g of bighead atractylodes rhizome, 2g of pseudo-ginseng powder, 20g of spreading hedyotis herb, 8g of poria cocos, 4g of coptis chinensis, 6g of curcuma zedoary and 10g of dandelion.
Example 4 Erbai san Qi Xiao Zheng Tang pharmacodynamics experiment
1. Subject: SPF grade SD male rats, 200 + -10 g
2. Animal grouping: the normal control group, the model group, the stomach rejuvenation control group, the "panax notoginseng anti-disease decoction" prevention group (prevention group) and the "panax notoginseng anti-disease decoction" treatment group were 5 groups in total, and 10 rats in each group.
3. Molding method
Except for 10 normal groups, molding is carried out. And (4) combining the literature and the pre-experimental result to simulate the modeling by adopting a comprehensive method mainly based on chemical damage. Presetting a molding scheme: the drinking water is composed of 167 mug/ml of N-methyl-N ' -nitro-N ' -nitrosoguanidine (N-methyl-N ' -nitro-N-nitrosoguanidine. MNNG) solution per day, and simultaneously 1ml of MNNG solution with the concentration of 0.017mol/L is gavaged in the afternoon; during the molding period, food is fed for 2 days, fasting is carried out for 1 day, and the stomach is drenched with 40% alcohol at the speed of 10ml/kg in the afternoon on the fasting day. For 10 consecutive weeks.
4. Method of administration
The equivalent dose of the drug administration of the rat is calculated according to an equivalent stoichiometric ratio value table converted according to the body surface area between the human and the animal, and 2 ml/rat is decocted in the stomach. The prevention and treatment group of 'Erbai pseudo-ginseng decoction for eliminating mass' is to give corresponding traditional Chinese medicine decoction at the beginning of molding. The treatment group and the control group of Fuchun are respectively administered with corresponding Chinese medicinal water decoction 11 weeks after molding. The normal control group and the model control group are treated by infusing physiological saline with the same volume in the beginning of 11 weeks after the model building for 6 weeks. Pentobarbital sodium (0.045 g kg) was administered to each group of rats at the end of 16 weeks -1 ) Intraperitoneal injection, after anesthesia, taking blood from abdominal aorta, cutting abdomen, taking stomach, washing gastric cavity with 0.9% NaCl solution, fixing gastric antrum in 4% paraformaldehyde, and storing the same parts of stomach lesser curvature, stomach greater bay and stomach fundus in a low temperature refrigerator at-80 deg.C with RNA store solution. The residual stomach tissue is stored in a low-temperature refrigerator at minus 80 ℃, animal carcasses are knotted and sealed by special plastic bags, are stored in the refrigerator at minus 18 ℃ firstly, and then are conveyed to a professional sanitary treatment plant together with other experimental wastes for harmless incineration treatment.
5. Results of the experiment
5.1 referring to the classification and diagnostic criteria of experimental gastric cancer, the compound Chinese medicine preparation 'Erbai san xiao zhen Tang' for treating gastric precancerous lesions in example 1 was used to count the number of cases of chronic superficial gastritis, chronic atrophic gastritis, intestinal metaplasia and atypical hyperplasia of rats before and after administration (see Table 1).
TABLE 1 Erbai san xiao zhen Tang for prevention and treatment of pathological conditions of precancerous lesion of stomach cancer
Note: n represents the number of animals, and the pathological judgment standard, the specification of diagnosis and treatment of newly-compiled common malignant tumors, gastric cancer booklet.
The results according to table 1 show that: compared with the normal group, the pathological changes of the model group are more obvious and the serious incidence rate is higher in different stages of chronic superficial gastritis → chronic atrophic gastritis → intestinal metaplasia → atypical hyperplasia gastric precancerous lesions. Compared with a model group, the prevention and treatment group and the treatment group of the 'Erbai pseudo-ginseng disease-eliminating decoction' can better improve pathological changes, and particularly have obvious curative effects on the aspects of slowing down intestinal metaplasia and atypical hyperplasia of middle and severe diseases in the middle and later stages.
5.2 the curative effect of the 'Erbai san Xiao Zheng Tang' is verified by means of histological change of gastric mucosa (see figure 1).
The results show that: compared with the normal group, the pathological change of the model group is obvious, and the structure of the gastric mucosa is seriously damaged. Compared with the model group, the prevention and treatment group and the treatment group of the 'Erbai pseudo-ginseng Xiaozheng decoction' can better improve pathological changes and repair gastric mucosa injury.
5.3 the Erbai Sanqi Xiaozheng Tang can activate the negative regulator, cytokine signal transduction inhibitory protein 3 (SOCS 3), upstream of Janus kinase 1/Signal transduction and transcription activator 3 (JAK 1/STAT 3), and then reduce the high expression of JAK1/STAT 3. Meanwhile, the method can reduce the high expression of Epidermal Growth Factor Receptor (EGFR), shows that the method can regulate and control a JAK1/STAT3 signal channel mediated by the EGFR and plays a role in preventing and treating gastric precancerous lesions (see tables 2, 3 and 4).
TABLE 2 influence of Erbai san Qi Xiao Zheng Tang on EGFR expression
Note: the method comprises the steps of immunohistochemistry; p <0.05, P <0.01; Δ P >0.05 compared to normal group.
TABLE 3 influence of Erbai san Qi Xiao Zheng Tang on SOCS3 expression
Note: the method comprises the steps of immunohistochemistry; p <0.05, P <0.01; Δ P >0.05 compared to normal group.
TABLE 4 Effect of 'Erbai san Xiao Zheng Tang' on JAK1/STAT3 expression
Note: the method comprises enzyme-linked immunosorbent assay; p <0.05, P <0.01; Δ P >0.05 compared to normal group.
5.4 Erbai Sanqi Xiaozheng Tang can reduce the expression of keratin 20 (CK 20) and cyclooxygenase-2 (COX-2) as tumor markers of rats with gastric precancerous lesions (see Table 5).
TABLE 5 Effect of Erbai san Qi Xiaozheng Tang on CK20 and COX-2 expression
Note: the method comprises the steps of immunohistochemistry; p <0.05, P <0.01; Δ P >0.05 compared to normal group.
In conclusion, the 'Erbai Sanqi Xiaozheng decoction' can effectively prevent and treat the occurrence and the development of gastric precancerous lesions, particularly slow down intestinal metaplasia and atypical hyperplasia at the middle and later stages, and reduce the expression of tumor marker cells keratin 20 (CK 20) and cyclooxygenase-2 (COX-2) of a rat with gastric precancerous lesions. Can activate cytokine signal transduction inhibitory protein 3 (SOCS 3), reduce high expression of Epidermal Growth Factor Receptor (EGFR), janus kinase 1/signal transduction and transcription activator 3 (JAK 1/STAT 3) in gastric precancerous lesion, and regulate and control signal pathway of EGFR induced JAK 1/STAT.
Claims (10)
1. A traditional Chinese medicine compound preparation for treating gastric precancerous lesion is named as Erbai pseudo-ginseng disease-eliminating decoction, and is characterized by being a traditional Chinese medicine composition prepared from the following raw material medicines in parts by weight: 7-12 parts of bighead atractylodes rhizome, 1-5 parts of pseudo-ginseng powder, 28-32 parts of spreading hedyotis herb, 10-14 parts of poria cocos, 4-8 parts of coptis chinensis, 8-12 parts of curcuma zedoary and 13-17 parts of dandelion.
2. The traditional Chinese medicine compound preparation for treating gastric precancerous lesions according to claim 1 is characterized by being prepared from the following raw material medicines in parts by weight: 8 to 10 parts of bighead atractylodes rhizome, 2 to 4 parts of pseudo-ginseng powder, 29 to 31 parts of spreading hedyotis herb, 11 to 13 parts of poria cocos, 5 to 7 parts of coptis chinensis, 9 to 11 parts of curcuma zedoary and 14 to 16 parts of dandelion.
3. The traditional Chinese medicine compound preparation for treating gastric precancerous lesions according to claim 1 is characterized by being prepared from the following raw material medicines in parts by weight: 9 parts of bighead atractylodes rhizome, 3 parts of pseudo-ginseng powder, 30 parts of spreading hedyotis herb, 12 parts of poria cocos, 6 parts of coptis chinensis, 10 parts of curcuma zedoary and 15 parts of dandelion.
4. A preparation method of a traditional Chinese medicine compound preparation for treating gastric precancerous lesion is characterized by comprising the following steps:
weighing the above materials according to the weight ratio of claim 1, placing the materials except for the radix Notoginseng powder in a pot, weighing 2 times of water, pouring the water into the pot, soaking the materials for 0.5h, decocting with strong fire to boil, boiling with slow fire for 0.5h, filtering with eight layers of clean medical gauze, pouring into a clean container, keeping the residue, adding water with the same volume as the first time, decocting, repeating the above steps, mixing the filtrates, adding radix Notoginseng powder, stirring, and warm-taking.
5. A granule for treating chronic gastritis and gastric precancerous lesions, which comprises the traditional Chinese medicine composition and preparation auxiliary materials of claim 1; the preparation auxiliary materials are one or more of filling agent, adhesive, wetting agent, disintegrating agent, lubricant and film coating material.
6. An oral liquid for treating chronic gastritis and gastric precancerous lesions, which comprises the traditional Chinese medicine composition and preparation auxiliary materials in claim 1; the preparation adjuvants are one or more of solvent, aromatic, correctant, clarifier and antiseptic.
7. A tablet for treating chronic gastritis and gastric precancerous lesions, which comprises the traditional Chinese medicine composition as claimed in claim 1 and preparation auxiliary materials; the preparation auxiliary materials are one or more of diluent, adhesive, lubricant and disintegrant.
8. A capsule for treating chronic gastritis and precancerous lesions of gastric cancer, which comprises the traditional Chinese medicine composition as claimed in claim 1 and preparation auxiliary materials; the preparation auxiliary material is a hard capsule shell or a soft capsule shell.
9. A powder for the treatment of chronic gastritis and precancerous lesions of gastric cancer, comprising the Chinese medicinal composition of claim 1.
10. The use of the Chinese medicinal composition of claim 1 in the preparation of a medicament for the treatment of chronic gastritis, chronic atrophic gastritis, precancerous lesions of gastric cancer, chronic atrophic gastritis with intestinal metaplasia and dysplasia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211496019.0A CN115671242A (en) | 2022-11-24 | 2022-11-24 | Traditional Chinese medicine compound preparation for treating gastric precancerous lesions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211496019.0A CN115671242A (en) | 2022-11-24 | 2022-11-24 | Traditional Chinese medicine compound preparation for treating gastric precancerous lesions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115671242A true CN115671242A (en) | 2023-02-03 |
Family
ID=85056876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211496019.0A Pending CN115671242A (en) | 2022-11-24 | 2022-11-24 | Traditional Chinese medicine compound preparation for treating gastric precancerous lesions |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115671242A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105833115A (en) * | 2016-04-29 | 2016-08-10 | 杜艳茹 | Traditional Chinese medicine for treating precancerous lesions of gastric cancer |
| CN112107662A (en) * | 2020-09-21 | 2020-12-22 | 河北省中医院 | Traditional Chinese medicine composition for treating chronic gastritis and precancerous lesions of gastric cancer and medicament and application thereof |
-
2022
- 2022-11-24 CN CN202211496019.0A patent/CN115671242A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105833115A (en) * | 2016-04-29 | 2016-08-10 | 杜艳茹 | Traditional Chinese medicine for treating precancerous lesions of gastric cancer |
| CN112107662A (en) * | 2020-09-21 | 2020-12-22 | 河北省中医院 | Traditional Chinese medicine composition for treating chronic gastritis and precancerous lesions of gastric cancer and medicament and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 王松坡,蔡淦,窦丹波,林江: "乐胃煎对大鼠胃癌前病变胃粘膜异型性的影响", 中国中西医结合消化杂志, no. 03, pages 145 - 147 * |
| 聂建华，等: "基于数据分析的"胃癌前病变"中医药精准治疗研究", 时珍国医国药, vol. 31, no. 12, pages 3047 - 3049 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105749179A (en) | Traditional Chinese medicine composition for treating metabolic syndrome | |
| CN104225441A (en) | Traditional Chinese medicine composition for treating stomach trouble and preparation method of granules and capsules of traditional Chinese medicine composition | |
| CN103520572A (en) | Traditional Chinese composition used for treating atopic dermatitis as well as preparation method of composition | |
| CN103735927B (en) | A kind of Chinese medicine composition for the treatment of acute stage of gout and preparation method thereof | |
| CN103405582A (en) | Traditional Chinese medicine composition for improving joint gall of rheumatoid arthritis | |
| CN105031454A (en) | Medicine for treating pulmonary tuberculosis | |
| CN1287830C (en) | Chinese traditional medicine compound preparation for treating gynecopathy and preparation method thereof | |
| CN102579610A (en) | Chinese medicinal composition for treating cerebral hemorrhage and preparation method thereof | |
| CN102552796B (en) | Chinese medicinal composition for treating chronic gastric ulcer | |
| CN115671242A (en) | Traditional Chinese medicine compound preparation for treating gastric precancerous lesions | |
| CN103536674B (en) | Medicament composition capable of preventing melanin tumor | |
| CN103041233A (en) | Pharmaceutical composition for treating infantile diarrhea and preparation method thereof | |
| CN112717097A (en) | Traditional Chinese medicine composition for treating gastric cancer and preparation method thereof | |
| CN100450537C (en) | Chinese medicinal formulation for treating prostate hyperplasia | |
| CN104740540A (en) | Heat-clearing and detoxifying preparation for treating appendicitis | |
| CN103735847B (en) | A kind of medicine and preparation method for the treatment of eczema | |
| CN103948899A (en) | Traditional Tibetan medicine for treating atrophic gastritis | |
| CN103127398B (en) | Chinese medicament for treating cancers and preparation method thereof | |
| CN103028028B (en) | Traditional Chinese medicine agent for treating primary hepatic carcinoma | |
| CN102430073A (en) | Medicinal composition for treating peptic ulcer | |
| CN107007697A (en) | One kind treats pelvic infecton or prostatitic Chinese medicine composition and its preparation | |
| CN102451330A (en) | Traditional Chinese medicine for treating sterility due to blood stasis | |
| CN101829188A (en) | Medicament for treating urinary infection and lithiasis | |
| CN102138948B (en) | Medicament for treating hyperlipidemia and coronary sclerosis and preparation method thereof | |
| CN106860646B (en) | Traditional Chinese medicine composition for treating gastroduodenal ulcer and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |